Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome
Roger G. Spragg(University of California San Diego Medical Center), Werner Seeger(Justus-Liebig-Universität Gießen), Guy A. Richards(University of the Witwatersrand), Jay A. Johannigman(University of Cincinnati), Geoff Bellingan(UCL Biomedical Research Centre), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), James F. Lewis(Western University), Gerd Rippin(Omnicare Pharma (Germany)), Michael C. Witte(Mercy Medical Center), Dietrich Häfner(Altana (Germany)), Friedemann Taut(Altana (Germany)), Hans‐Dieter Walmrath, F. Rathgeb(Altana (Germany))
Cited by 420
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Clinical classification of pulmonary hypertension
|Journal of the American College of Cardiology|2004|1.9k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855